THYCA THYROID CANCER SURVIVORS logo

ThyCa Medullary Thyroid Cancer Research Fund

THYCA THYROID CANCER SURVIVORS

Funding Amount

Varies

Deadline

Rolling / Open

Grant Type

foundation

Overview

ThyCa Medullary Thyroid Cancer Research Fund

Funder: ThyCa: Thyroid Cancer Survivors' Association, Inc.

Geographic Scope: International; open to researchers and institutions worldwide

Focus Areas: Research specifically focused on medullary thyroid cancer, including:

  • Pathogenesis of medullary thyroid cancer

  • Clinical aspects of the disease

  • Treatment of medullary thyroid cancer

  • Both sporadic and familial medullary thyroid cancer
  • Program Overview:
    ThyCa established the Medullary Thyroid Cancer Research Fund in 2003 as a second research fund to support research on medullary thyroid cancer specifically. Medullary thyroid cancer accounts for 5-10% of all thyroid cancer cases and has unique features distinct from follicular-cell-derived thyroid cancers.

      Key Features

    • Dedicated Focus: Specialized research fund separate from the general Thyroid Cancer Research Fund
    • Funding Structure: 100% of donated funds go directly to research
    • Selection Process: Independent peer review by expert scientific panel of the American Thyroid Association (ATA)
    • Grant Terms: Typically 2-year grants with continuation funding based on progress reports
    • Tax Deductible: All contributions are tax-deductible to the extent allowed by IRS

      Eligibility

    • Open to researchers at any hospital or research institution
    • International researchers eligible
    • Research proposals evaluated on scientific merit regardless of institution affiliation

      Donor Options

    • Donors may designate contributions specifically to the Medullary Thyroid Cancer Research Fund
    • Donors may also contribute to both the Medullary Thyroid Cancer Fund and the Thyroid Cancer Research Fund
    • Contributions of any size welcome

      Contact Information

    • Phone: 1-877-588-7904
    • Email: thyca@thyca.org
    • Mailing Address: ThyCa: Thyroid Cancer Survivors' Association, Inc., Research Fund, PO Box 1545, New York, NY 10159-1545
    • Website: www.thyca.org

      Notable Recipients

    • 2005/2007: Matthias Schott, M.D., Heinrich-Heine University of Duesseldorf, Germany - "Induction of Cytotoxic Immunity in Medullary Thyroid Carcinoma by Dendritic Vaccination"
    • 2006/2007: Xianmin Xia, Ph.D., Johns Hopkins University School of Medicine, Baltimore, Maryland - Research on tumor suppressor proteins affecting medullary thyroid cancer cells

    How to Apply

    Application Process

    Applications are submitted through the American Thyroid Association (ATA) portal:

    1. Visit: www.thyroid.org or the ATA professionals/education/grants section
    2. Submit Proposal Summary by announced deadline (e.g., March 15, 2005 for 2005 cycle)
    3. Selected Proposals: Authors invited to submit complete grant applications (typically due in spring)
    4. Expert Review: Scientific panel of the ATA conducts independent peer review
    5. Award Decision: Based on scientific merit and relevance to medullary thyroid cancer research

      Required Materials

    • Initial proposal summary
    • Complete grant application (if selected)
    • Progress reports (required in fourth quarter of first year for continuation funding)

      Notes

    • Check ATA website for current application deadlines and specific guidelines
    • Applications open to researchers worldwide
    • ThyCa coordinates with ATA for all review and selection processes
    • Focus must be specifically on medullary thyroid cancer research

    Focus Areas & Funding Uses

    Fields of Work

    science-researchcancer

    Categories

    Browse similar grants by category

    Related Grants

    Similar grants from this funder and related organizations

    Ready to apply for ThyCa Medullary Thyroid Cancer Research Fund?

    Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.